Plain-English translation of NCT07174570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for advanced liver cancer using three medications: (an anti-inflammatory drug), , and (two immunotherapy drugs that help your immune system fight cancer). The idea is that the anti-inflammatory medication may help the immunotherapy drugs work better by removing barriers that prevent them from attacking cancer cells.
Some patients with advanced liver cancer don't respond well to immunotherapy alone, or their cancer becomes resistant to it over time. Researchers believe that inflammation in and around tumors may be protecting the cancer from the immune system, so combining an anti-inflammatory medication with immunotherapy might overcome that resistance and improve treatment effectiveness.
You likely qualify if…
You likely don't qualify if…
You would take the anti-inflammatory medication by mouth twice daily for 28 days at a time, repeating this schedule in monthly cycles. On day 1 of each cycle, you would receive infusions of the two immunotherapy drugs through an IV line (the second drug is given only during cycle 1). Throughout the study, you would have regular blood tests and CT or MRI scans to monitor how the cancer is responding. After treatment ends, you would return for a check-up 30 days later and then every 12 weeks for up to 2 years.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States